Modest Increase in Market Share Expected for Western Drug Companies, According to a Report from Decision Resources
WALTHAM, Mass., April 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the colorectal cancer drug market in China will more than double by 2012, growing from $118 million in 2007 to $290 million in 2012. This growth will be fueled by a large increase in colorectal cancer incident cases, improvement in access to medical care and significantly increased prescribing of targeted therapies.
"The increased use of Merck KGaA's Erbitux and Jiangsu Simcere's Endostar and the launch of Roche's Avastin will be the strongest drivers of the Chinese colorectal drug market during the next five years," stated Jing Wu, M.S., MBA. "We also expect a high uptake of Roche's Xeloda -- an oral pro-drug of 5-fluorouracil (5-FU) -- due to its delivery advantage over intravenous 5-FU and its inclusion on the National Reimbursement Drug List."
The new Emerging Markets report entitled Colorectal Cancer in China also finds that modest increase in market share is expected for Western drug companies by 2012. This growth will result from the increased uptake of Western-branded, targeted agents and the decreasing market share of conventional chemotherapy drugs owing to fierce competition from domestic products. The report contains primary research of physicians and epidemiology study in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and Jinan.
About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report seri
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved